2018 Cerebral Ischemia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Cerebral Ischemia Market

June 2018 | 70 pages | ID: 2388C84F049EN
VPAResearch

Abstracts

Cerebral ischemia or Brain ischemia condition refers to inadequate blood supply to the brain to enable it to cater its regular metabolic requirements. This can result in brain tissue death, ischemic stroke, hemorrhage, resulting in loss of movement, speech and vision difficulties, impact on memory, weakness, unconsciousness etc. Depending on the affected area in the brain, Cerebral Ischemia is classified as focal (certain area in the brain) and global (large portion of the brain). Analgesics, Anti- platelet drugs and BP controlling drugs are typically administered.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Cerebral Ischemia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Cerebral Ischemia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Cerebral Ischemia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 CEREBRAL ISCHEMIA PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Cerebral Ischemia Pipeline Snapshot
2.3 Cerebral Ischemia Pipeline by Phase
2.4 Cerebral Ischemia Pipeline by Company
2.5 Cerebral Ischemia Pipeline by Mechanism of Action

3 CEREBRAL ISCHEMIA- COMPANY WISE PIPELINE ANALYSIS

Aranda Pharma Ltd
Aronora Inc
CohBar Inc
Lixte Biotechnology Holdings
NeuroNascent Inc
NeurOp Inc
NoNO Inc
Prolong Pharmaceuticals, LLC
Vect-Horus SAS

4 CEREBRAL ISCHEMIA R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN CEREBRAL ISCHEMIA PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Cerebral Ischemia Pipeline by Phase, H2- 2018
Figure 2: Cerebral Ischemia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Cerebral Ischemia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Cerebral Ischemia Pipeline by Phase, H2- 2018
Cerebral Ischemia Pipeline by Companies, H2- 2018
Cerebral Ischemia Pipeline by Mechanism of Action, H2- 2018
Table 1: Aranda Pharma Ltd Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 2: Aronora Inc Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 3: CohBar Inc Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 4: Lixte Biotechnology Holdings Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 5: NeuroNascent Inc Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 6: NeurOp Inc Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 7: NoNO Inc Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 8: Prolong Pharmaceuticals, LLC Cerebral Ischemia Pipeline Drugs, H2- 2018
Table 9: Vect-Horus SAS Cerebral Ischemia Pipeline Drugs, H2- 2018